Terrence Kearney
Director
Audit and Finance Committee, Member
Management Development and Compensation Committee, Member
Mr. Kearney joined our board in 2011. He served as the Chief Operating Officer of Hospira, Inc., a specialty pharmaceutical and medication delivery company, from April 2006 to January 2011. From April 2004 to April 2006, he served as Hospira’s Senior Vice President, Finance, and Chief Financial Officer, and he served as Acting Chief Financial Officer through August 2006. Mr. Kearney served as Vice President and Treasurer of Abbott Laboratories from 2001 to April 2004. From 1996 to 2001, Mr. Kearney was Divisional Vice President and Controller for Abbott’s International Division. Mr. Kearney served as a member of the board of directors at Levo Therapeutics, Inc., a biotechnology company focused on developing treatments for Prader-Willi Syndrome, from 2018 to June 2022, and served as a member of the board of directors at Acceleron Pharma Inc., a biopharmaceutical company, from July 2014 until it was acquired by Merck in November 2021. He served as a member of the board of directors of Innoviva (formerly known as Theravance, Inc.), a royalty management company, from October 2014 through April 2016, and as member of the board of directors of AveXis, Inc., a gene therapy company, from January 2016 until its acquisition in May 2018. He received his B.S. in biology from the University of Illinois and his M.B.A. from the University of Denver.
Mr. Kearney joined our board in 2011. He served as the Chief Operating Officer of Hospira, Inc., a specialty pharmaceutical and medication delivery company, from April 2006 to January 2011. From April 2004 to April 2006, he served as Hospira’s Senior Vice President, Finance, and Chief Financial Officer, and he served as Acting Chief Financial Officer through August 2006. Mr. Kearney served as Vice President and Treasurer of Abbott Laboratories from 2001 to April 2004. From 1996 to 2001, Mr. Kearney was Divisional Vice President and Controller for Abbott’s International Division. Mr. Kearney served as a member of the board of directors at Levo Therapeutics, Inc., a biotechnology company focused on developing treatments for Prader-Willi Syndrome, from 2018 to June 2022, and served as a member of the board of directors at Acceleron Pharma Inc., a biopharmaceutical company, from July 2014 until it was acquired by Merck in November 2021. He served as a member of the board of directors of Innoviva (formerly known as Theravance, Inc.), a royalty management company, from October 2014 through April 2016, and as member of the board of directors of AveXis, Inc., a gene therapy company, from January 2016 until its acquisition in May 2018. He received his B.S. in biology from the University of Illinois and his M.B.A. from the University of Denver.